Navigation Links
BioreclamationIVT Signs Exclusive Agreement To Distribute Cellaria Cell Models And Media For Cancer Research
Date:4/13/2017

WESTBURY, N.Y., April 13, 2017 /PRNewswire/ -- BioreclamationIVT, a leading provider of biospecimens and related services, has signed a new distribution partnership agreement with Cellaria, LLC. According to the terms of the agreement, BioreclamationIVT will have exclusive market and distribution rights to Cellaria's novel cancer cell lines and cancer culture media in the United States and Canada and non-exclusive rights to sell the products globally. The agreement expands the availability of Cellaria's offerings to a broader range of potential customers via an established distribution partner with existing relationships inside the biopharmaceutical industry.

Designed to accelerate cancer research, the Cellaria cell models are derived directly from patient tumors with fully consented, fully documented pathological data. A unique feature of the cell models is their ability to maintain the fidelity of primary cells, with no genetic manipulation, while still offering the long-term reproducibility and scalability seen with traditional tumor cell lines. In addition to the cell lines, BioreclamationIVT will also distribute Cellaria's proprietary media which is specifically formulated to extend in vitro propagation of primary tumor and epithelial cells.  

David Deems, president of Cellaria Biosciences, said, "As a trusted partner to leading biopharmaceutical companies, BioreclamationIVT supports our goals of providing oncology researchers with more actionable data during their development of personalized therapeutics."

"Cellaria products represent an important addition to our rapidly growing disease-state matrices portfolio," said Jeff Gatz, CEO of BioreclamationIVT. "This distribution partnership leverages the strengths of both companies and ensures that we will continue to deliver relevant tools and services for our clients focused on disease research."

About Cellaria
Cellaria creates high-quality next generation in-vitro disease models that reflect the unique nature of a patient's biology. All of our models begin with tissue from a patient, capturing clinically relevant details that inform model characterization. For cancer, Cellaria's cell models exhibit molecular and phenotypic characteristics that are highly concordant to the patient. For RNA-mediated iPS cell line derivation, Cellaria's cell models enable interrogation of disease-specific mechanisms of action. Cellaria's innovative products and services help lead the research community to more personalized therapeutics – revolutionizing and accelerating the search for a cure. 

About BioreclamationIVT
BioreclamationIVT is a worldwide provider of biological products to the life sciences and pharmaceutical industries. BioreclamationIVT specializes in control and disease-state matrices manufactured from human and animal biological specimens and has recently expanded its offering to include cell processing and phenotypic screening services. This portfolio of products is utilized throughout the drug discovery and development research workflows, and directly supports the personalized medicine initiative by coupling clinical information with numerous disease-state fluids and tissues. BioreclamationIVT's reputation for providing exceptional customer service coupled with the highest quality specimens and services have made it the first-choice supplier for biospecimens for more than 35 years. For more information, please visit http://www.bioreclamationivt.com.

BioreclamationIVT Contact: Courtney Noah, Vice President of Marketing, 516-483-1196
Cellaria Contact: Tim Walsh, 617-512-1641, timw@walshgroupmarketing.com 
Media Contact: Lisa Osborne, Rana Healthcare Solutions, 206-992-5245, lisa@ranahealth.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioreclamationivt-signs-exclusive-agreement-to-distribute-cellaria-cell-models-and-media-for-cancer-research-300439211.html


'/>"/>
SOURCE BioreclamationIVT
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Hemp, Inc. Signs Letter of Intent with One of Chinas Largest Agricultural Producers, Yasheng Group
2. Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc.
3. PharmaRoth Labs Signs Definitive Distribution Agreement in Mexico
4. Premier Healthcare Alliance [GPO] Re-Signs with Sysmex America, Inc. for 15th Consecutive Year
5. Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
6. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
7. Breckenridge Pharmaceutical signs Letter of Intent with Welding GmbH & Co & SK Chemicals
8. MD Anderson Signs Contract For Pyxis ES Technology From CareFusion
9. Masimo Signs Far-Reaching Pulse Oximetry Distribution Deal with Butler Schein Animal Health
10. Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
11. Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... , ... July 02, 2020 , ... AllenComm, the leader ... projects and four Omni Awards for visually compelling compliance training , onboarding ... to meet and exceed client and industry expectations as a digital transformation partner for ...
(Date:7/2/2020)... ... July 02, 2020 , ... ScripHessco has ... Chiropractors Treat. , “From migraines to anxiety to fibromyalgia, chiropractors have proven ... the company. , Sourced from physician recommendations on WebMD, US News, and ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... distributor, is pleased to announce its donation of more than $190,000 in personal ... of Health and Human Services. As extreme medical shortages continue to plague the ...
Breaking Medicine Technology:
(Date:7/10/2020)... TROY, Mich. (PRWEB) , ... July 10, 2020 ... ... can be overwhelming for people with spinal cord disease or injury and social ... the COVID-19 pandemic can induce symptoms of anxiety, depression, distress, and PTSD amongst ...
(Date:7/10/2020)... Calif. (PRWEB) , ... July 10, 2020 , ... Traliant, ... today announced a new training course for managers on the Family and Medical Leave ... FMLA with paid sick and family leave provisions related to COVID-19. , ...
(Date:7/7/2020)... ... July 07, 2020 , ... ... or two head design to efficiently sanitize large surfaces is now available in ... available to support sales in that region. , In this era of worldwide ...
(Date:7/2/2020)... ... ... Dr. Christine Blaine has earned a stellar reputation as one of ... Island, Huntington and NYC, NY. Her former Manhattan clinic, located at 1201 Broadway, ... NYC at 160 Madison Avenue. Blaine Plastic Surgery will be one of ...
(Date:7/1/2020)... IRVINE, Calif. (PRWEB) , ... July 01, 2020 ... ... production of cannabis and botanically-derived terpenes, has officially released its new terpene ... offering brands a way for consumers to enjoy cannabis terpene profiles and flavors ...
Breaking Medicine News(10 mins):